Cellular accumulation of fluoroquinolones is not predictive of their intracellular activity: studies with gemifloxacin, moxifloxacin and ciprofloxacin in a pharmacokinetic/pharmacodynamic model of uninfected and infected macrophages

Coralie M. Vallet, Béatrice Marquez, Eva Ngabirano, Sandrine Lemaire, Marie-Paule Mingeot-Leclercq, Paul M. Tulkens, Françoise van Bambeke

► **To cite this version:**

Coralie M. Vallet, Béatrice Marquez, Eva Ngabirano, Sandrine Lemaire, Marie-Paule Mingeot-Leclercq, et al.. Cellular accumulation of fluoroquinolones is not predictive of their intracellular activity: studies with gemifloxacin, moxifloxacin and ciprofloxacin in a pharmacokinetic/pharmacodynamic model of uninfected and infected macrophages. *International Journal of Antimicrobial Agents*, 2011, 10.1016/j.ijantimicag.2011.05.011 . hal-00722865

HAL Id: hal-00722865

<https://hal.science/hal-00722865>

Submitted on 6 Aug 2012

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Accepted Manuscript

Title: Cellular accumulation of fluoroquinolones is not predictive of their intracellular activity: studies with gemifloxacin, moxifloxacin and ciprofloxacin in a pharmacokinetic/pharmacodynamic model of uninfected and infected macrophages

Authors: Coralie M. Vallet, Béatrice Marquez, Eva Ngabirano, Sandrine Lemaire, Marie-Paule Mingeot-Leclercq, Paul M. Tulkens, Françoise Van Bambeke

PII: S0924-8579(11)00252-4
DOI: doi:10.1016/j.ijantimicag.2011.05.011
Reference: ANTAGE 3636

To appear in: *International Journal of Antimicrobial Agents*

Received date: 22-3-2011
Revised date: 14-5-2011
Accepted date: 17-5-2011

Please cite this article as: Vallet CM, Marquez B, Ngabirano E, Lemaire S, Mingeot-Leclercq M-P, Tulkens PM, Van Bambeke F, Cellular accumulation of fluoroquinolones is not predictive of their intracellular activity: studies with gemifloxacin, moxifloxacin and ciprofloxacin in a pharmacokinetic/pharmacodynamic model of uninfected and infected macrophages, *International Journal of Antimicrobial Agents* (2010), doi:10.1016/j.ijantimicag.2011.05.011

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Cellular accumulation of fluoroquinolones is not predictive of their intracellular activity: studies with gemifloxacin, moxifloxacin, and ciprofloxacin in a pharmacokinetic/pharmacodynamic model of uninfected and infected macrophages.

Coralie M. Vallet, Béatrice Marquez,[§] Eva Ngabirano, Sandrine Lemaire, Marie-Paule Mingeot-Leclercq, Paul M. Tulkens*, and Françoise Van Bambeke

Pharmacologie cellulaire et moléculaire, Louvain Drug Research Institute, Université catholique de Louvain, Brussels, Belgium

Running title: Cellular pharmacokinetics and activity of fluoroquinolones

[§] Present address: Grupo Tumorigenesis endocrina y regulación hormonal del cáncer, Instituto de Biomedicina de Sevilla - Hospitales Universitarios Virgen del Rocío, Avenida Manuel Siurot s/n, 41013 Sevilla, Spain.

*** Corresponding author**

Pharmacologie cellulaire et moléculaire,
Université catholique de Louvain,
Avenue E. Mounier 73 bte B1.73.05,
B-1200 Bruxelles, Belgium.
Phone: +32-2-764-73-71.
Fax: +32-2-764-73-73.
E-mail: tulkens@facm.ucl.ac.be

ABSTRACT

Fluoroquinolones enter eukaryotic cells but the correlation between cellular accumulation and activity remains poorly established. Gemifloxacin is known to accumulate to a larger extent than most other fluoroquinolones in tissues. Using murine J774 macrophages and human THP-1 monocytes, we show that gemifloxacin accumulates more than ciprofloxacin and even moxifloxacin. While showing indistinguishable kinetics of accumulation in J774 macrophages, gemifloxacin was released at an approximately two-fold slower rate than ciprofloxacin and its release was only partial. Gemifloxacin was also a weaker substrate than ciprofloxacin for the efflux transporter Mrp4 active in J774 macrophages. In cells infected with *L. monocytogenes* or *S. aureus* (typical cytoplasmic and phagolysosomal organisms, respectively), gemifloxacin was equipotent to moxifloxacin and ciprofloxacin in concentration-dependent experiments if data are normalized based on MIC in broth. Thus, larger cellular concentrations of gemifloxacin than of moxifloxacin or ciprofloxacin were needed to obtain a similar target effect. Fractionation studies showed a similar subcellular distribution for all 3 fluoroquinolones, with about 2/3 of the cell-associated drug recovered in the soluble fraction (cytosol). The data suggest that the cellular accumulation of fluoroquinolones is largely a self-defeating process as far as activity is concerned, with the intracellular drug made inactive in proportion to its accumulation level. While these observations do not decrease the intrinsic value of fluoroquinolones for treatment of intracellular infections, they indicate that ranking fluoronolones based on cell accumulation data without measuring the corresponding intracellular activity may lead to incorrect conclusions concerning their real potential.

Keywords: ciprofloxacin, moxifloxacin, gemifloxacin, Mrp4, *Staphylococcus aureus*, *Listeria monocytogenes*, macrophages

1. Introduction

Fluoroquinolone antibiotics are important in our current therapeutic arsenal, because of their broad spectrum, highly bactericidal activity, and favourable pharmacokinetic properties [1]. Their wide tissue distribution allows them reaching therapeutic concentrations in deep body compartments as well as in the intracellular milieu, which may be an advantage in the treatment of intracellular infections. Accumulation and activity in cells are usually linked when considering a given fluoroquinolone in a specific cell type, as demonstrated for ciprofloxacin *vis-à-vis* the intracellular forms of *L. monocytogenes* in J774 macrophages in experiments where its cellular concentration was modulated by inhibition or overexpression of the constitutive ciprofloxacin efflux transporter Mrp4 [2;3]. There is, however, a lack of quantitative data comparing distinct fluoroquinolones in this context.

Gemifloxacin [4] accumulates to high levels in human PMN and is active against intracellular bacteria [5;6]. This prompted us to compare it to other fluoroquinolones for cellular pharmacokinetics and activity in an established model of murine J774 macrophages [7]. Ciprofloxacin and moxifloxacin, **when needed**, were used comparators, as these show a low and large accumulation, respectively, in relation to differential susceptibility to efflux [8-11]. We also examined THP-1 cells, where no active fluoroquinolone efflux has been evidenced so far. We found that gemifloxacin accumulates to higher levels than ciprofloxacin and moxifloxacin in both cell types and that all three drugs have a similar subcellular distribution. Yet, gemifloxacin showed no improved activity against two types of intracellular bacteria, *L. monocytogenes* and *S. aureus*, localized in the cytosol and in phagolysosomes, respectively.

2. Materials and methods

2.1. Antibiotics and main reagents

Gemifloxacin mesylate (LG Life Sciences, Seoul, Korea), and ciprofloxacin-HCl and moxifloxacin-HCl (Bayer HealthCare AG, Leverkusen, Germany) were obtained as microbiological standards (potencies: 79 %, 85 %, and 91 %). Gemfibrozil was from Sigma-Aldrich (St-Louis, MO, USA), human serum from Lonza Ltd (Basel, Switzerland), and cell culture media and sera from Invitrogen Corp. (Carlsbad, CA).

2.2. Cell lines

Murine J774 macrophages (wild-type cells [9]) and their ciprofloxacin-resistant derivatives overexpressing Mrp4 efflux transporter [8;11] were used for most experiments. Human THP-1 cells (ATCC TIB-202, American Tissue Culture Collection, Manassas, VA) [12;13] were used for comparison purposes. ATP depletion was obtained as previously described [9].

2.3. Determination of the cellular accumulation of fluoroquinolones.

We used a previously described protocol [9;14]. Cell -associated fluoroquinolones were assayed by fluorimetry (see [10] for ciprofloxacin and moxifloxacin; for gemifloxacin, the conditions were: $\lambda_{\text{ex.}}$ = 270nm; $\lambda_{\text{em.}}$ = 402 nm [lowest limit of detection: 50 µg/L; linearity: 0-1.5 mg/L]). The cell drug content was expressed by reference to the total cell protein content [15]. The apparent total cellular concentration was then calculated using a conversion factor of 3.08 µL of cell volume per mg of cell protein [9].

2.4. Cell fractionation studies in J774 cells

The main subcellular organelles were separated by differential centrifugation as previously described [2]. The protein and antibiotic content of each fraction was determined in parallel with the activity of marker enzymes of the main organelles (cytochrome c-oxidase for mitochondria; N-acetyl-β-hexosaminidase for lysosomes, and lactate dehydrogenase for cytosol [7]).

2.5. *Bacterial strains and susceptibility testings.*

We used *L. monocytogenes* strain EGD and *S. aureus* strain ATCC 25923. MIC determinations were made according to CLSI guidelines [16], using Tryptic Soy broth for *L. monocytogenes* [13] and Mueller Hinton broth for *S. aureus* [14].

2.6. *Cell infection and assessment of antibiotic intracellular activities.*

Cell infection was performed as described previously [2], with pharmacological comparison between drugs and bacteria based on concentration-dependent effects analyses [14], to determine (i) the relative minimal and maximal efficacies ($E_{\min}$ / $E_{\max}$, in $\log_{10}$ units), and (ii) the relative potencies (EC_{50}) and static concentrations). This type of analysis and its usefulness for comparing antibiotics and the response of different bacteria has been described in details in previous publications [14;17-19]). As discussed previously [20], the large dilution of samples before spreading on agar plates for cfu counting ensures an absence of carry-over effect.

2.7. *Curve fitting and statistical analyses*

Curve-fitting analyses were made using GraphPad Prism® version 4.03, GraphPad Software, San Diego, CA, USA. Statistical analyses were made with the same software for comparing concentration-response functions and with GraphPad Instat® version 3.06 (GraphPad Software) for other studies.

3. Results

3.1. Cellular pharmacokinetics

We first compared the cellular accumulation of gemifloxacin with that of ciprofloxacin and moxifloxacin, and examined the influence of gemfibrozil, a broad spectrum inhibitor of anion transporters including the Mrp transporters, on this accumulation. Figure 1A (upper panels) shows that (i) gemifloxacin accumulated to a larger extent than the other two fluoroquinolones in both J774 and THP-1 cells; (ii) the accumulation of gemifloxacin and moxifloxacin was not influenced by gemfibrozil; (iii) in contrast, ciprofloxacin, which accumulated to the lowest extent in J774 macrophages, reached a cellular concentration similar to that of moxifloxacin in these cells in the presence of gemfibrozil, as already observed in the same model [10]; (iv) the level of accumulation of ciprofloxacin was similar to that of moxifloxacin in THP-1 cells and not influenced by the addition of gemfibrozil.

We then compared the kinetics of accumulation and efflux of gemifloxacin with that of ciprofloxacin using J774 macrophages only as this is where the largest difference of accumulation was observed. Figure 1B shows that the two fluoroquinolones could not be distinguished with respect to accumulation kinetics but displayed marked differences for efflux. Thus, gemifloxacin release (i) occurred at the same rate as its uptake (compare k_{in} and k_{out} parameters); (ii) was about 2-fold slower than that of ciprofloxacin, including at the very initial period phase (see inset); (iii) was only partial, with about 25 % of the accumulated drug remaining cell-associated in apparent stable fashion after 30 min incubation in drug-free medium vs. negligible amounts for ciprofloxacin.

We next measured the level of accumulation of gemifloxacin compared to that of ciprofloxacin in J774 macrophages overexpressing the ciprofloxacin efflux transporter Mrp4 (ciprofloxacin-resistant cells), using normal conditions and conditions of ATP depletion (which inhibits all ATP-dependent active transporters including Mrp4). Figure 2A (upper

panels) shows that (i) gemifloxacin accumulation was reduced (but in a non-statistically significant manner) in ciprofloxacin-resistant cells compared to wild-type cells; (ii) ATP depletion increased its accumulation in both wild-type and ciprofloxacin-resistant cells, but with a significant difference in the latter cells only; (iii) ciprofloxacin accumulation was significantly reduced in ciprofloxacin-resistant cells, but was markedly increased by ATP depletion, reaching a value similar to that observed in wild-type cells after ATP depletion; (iv) in line with our previous observations [11], ATP depletion markedly increased the accumulation of ciprofloxacin in wild-type cells.

Because the ciprofloxacin efflux transporter is saturable in a 10-200 mg/L range [9], we measured the accumulation of gemifloxacin in both wild-type J774 macrophages and ciprofloxacin-resistant cells over increasing concentrations of gemifloxacin in that range. Figure 2 (lower panel) shows that while gemifloxacin accumulation was not significantly influenced by its extracellular concentration in wild-type cells, there was a significant increase over the range of concentrations investigated for ciprofloxacin-resistant cells. In contrast, and as described earlier [9], ciprofloxacin showed a marked increase in its accumulation over the same concentration range in wild-type cells. For ciprofloxacin-resistant cells, the increase in cell accumulation of ciprofloxacin was much less marked in the range of drug concentrations investigated due to overexpression of the Mrp4 transporter (see [11]).

These results suggest that gemifloxacin could be a poor, albeit still recognized substrate for efflux transport in J774 macrophages if Mrp4 is overexpressed. We, therefore, compared the kinetics of gemifloxacin efflux in ciprofloxacin-resistant vs. wild-type cells. While the *plateau* values observed at 30 min remained close from each other, denoting an incomplete release of gemifloxacin in both cases, its rate of efflux was significantly accelerated in ciprofloxacin-resistant cells compared to wild-type cells ($k_{out} = 2.393 \pm 0.907$ vs. 0.403 ± 0.122 min⁻¹; $p < 0.001$; see graphical representation in Figure SP1 in the Supplementary Material).

3.2. Intracellular activity

To examine the correlation between cellular accumulation and intracellular activity, we compared all 3 fluoroquinolones in our pharmacological model of intracellular infection [14;17], using J774 macrophages since this is where the largest differences in accumulation levels had been observed. *L. monocytogenes* and *S. aureus* were selected as bacterial targets as they represent a typical cytoplasmic and phagolysosomal organism, respectively. Data presented in Figure 3A (with analysis of the key pharmacological descriptors in Table 1) show that all 3 antibiotics induced essentially a similar response when expressed as a function of equipotent extracellular concentrations (multiples of MIC). Thus, in all cases, a single sigmoid function could be fitted to the individual responses of each antibiotic (see Figure SP2 in the Supplementary Material and the pertinent regression parameters and pharmacological descriptors in Table 1). As no statistically significant difference was observed between the 3 antibiotics, all data were pooled to fit a single function shown in Figure 3A. Thus, for each bacterium, the relative minimal efficacies ($E_{\min}$ [growth in the absence of antibiotic]), maximal relative efficacies ($E_{\max}$ [maximal antibiotic-related killing]), relative potencies (E_{50}), and static concentrations (C_s ; [in multiples of MIC) were not statistically significantly different. We then calculated for each fluoroquinolone which cellular drug concentration would be needed to reach two predefined pharmacodynamic targets (static effect and a 1 or 2 $\log_{10}$ cfu decrease). The results (with the mode of calculation) are presented in Figure 3B and show that the potencies of the drugs with respect to their intracellular targets is in inverse proportion to their respective cellular accumulations.

3.3. Subcellular distribution

Lastly, we compared the subcellular distributions of ciprofloxacin, moxifloxacin, and gemifloxacin. Figure 4 shows that all 3 fluoroquinolones shared essentially the same distribution, with about 70 % recovered in the soluble fraction, about 10 % of ciprofloxacin and gemifloxacin and 18 % of moxifloxacin in the nuclei/unbroken cells fraction, and the

211 remaining in the organelles/membranes fraction. As previously described [7], lactate
212 dehydrogenase was mostly recovered in the soluble fraction, and cytochrome oxydase and
213 N-acetyl- β -hexosaminidase, in the granules/membranes fraction, indicating that the
214 fractionation method effectively separated the corresponding subcellular entities with only a
215 very low proportion of unbroken cells left after homogenization.

216

4. Discussion

Gemifloxacin, approved for clinical use in over 27 countries [21], is characterized by very low MICs against Gram-positive bacteria [22;23] related to the presence of an oximinomethyl group [4] in its C7 side-chain and by a high tissular accumulation [24]. Human PK/PD studies show that gemifloxacin achieves higher AUC/MIC ratios in epithelial lining fluid and alveolar macrophages than other currently used fluoroquinolones, suggesting an advantage in terms of availability and efficacy at the site of infection [25;26]. The present study, however, shows that the higher accumulation of gemifloxacin in J774 macrophages (i) is not associated with differences in influx rates compared to a fluoroquinolone with lower accumulation (ciprofloxacin); (ii) does not preclude and cannot be explained by differences in active efflux transport (in comparison with moxifloxacin); (iii) does not lead to a higher intracellular activity. This goes against commonly accepted pharmacokinetic and pharmacodynamic concepts that tend to link accumulation and lack of efflux on the one hand, and accumulation and activity on the other hand. Our model may be questioned, but it is important to note that it reproduces (i) with respect to pharmacokinetics, what is observed in human alveolar macrophages where the concentrations of ciprofloxacin, moxifloxacin, and gemifloxacin are respectively 2-5 x, 20-40 x, and 90 x higher than serum levels [26-28], and (ii) with respect to intracellular activity what has been observed in human polymorphonuclear leucocytes infected by *S. aureus* [5].

Mechanistically, differences in accumulation of drugs in cells and tissues usually result from commensurate differences in influx or efflux rates, or from differential trapping by intracellular organelles or constituents.

Considering influx first, faster drug accumulation is usually related to a higher lipophilicity (which is supposed to facilitate transmembrane diffusion) or from the activity of transporters. This does not seem to apply to gemifloxacin, as this fluoroquinolone (i) is not globally more lipophilic than ciprofloxacin (see Table SP1 for experimental and calculated log P and log D

values), (ii) is probably not the substrate of a specific influx transporter when compared to ciprofloxacin (same rate accumulation constants). Non-specific influx transporter(s) observed in PMN and human monocytes [29-31] can probably be dismissed here as these belong to the Solute Carrier Organic Anion (SLCO) family [32] that is inhibited by gemfibrozil, which was not the case here.

Considering efflux, Mrp4 has been proposed as the main transporter responsible for the lower accumulation of ciprofloxacin in J774 macrophages compared to levofloxacin, garenoxacin, and moxifloxacin. These fluoroquinolones, indeed, reach a similar level of accumulation when Mrp4 is made inactive by ATP depletion or addition of gemfibrozil [10]. Moreover, ciprofloxacin accumulation is significantly increased by silencing the gene coding for Mrp4 [8]. The present data show that this conclusion cannot be generalized to all fluoroquinolones and all situations. Thus gemifloxacin not only accumulates more than moxifloxacin in J774 macrophages under conditions of ATP depletion or in the presence of gemfibrozil, but also in THP-1 macrophages in which no gemfibrozil-inhibited efflux can be demonstrated. Another compelling reason to disregard efflux as being the main cause for the differential accumulation of gemifloxacin vs. ciprofloxacin and moxifloxacin is that gemifloxacin actually seems a weak but nevertheless effective substrate of Mrp4 in J774 macrophages, whereas we know that moxifloxacin is not. Thus, globally and in contrast to what we proposed for moxifloxacin, the higher cellular concentration of gemifloxacin compared to other fluoroquinolones must find an explanation beyond considerations of influx and efflux rates only.

Considering intracellular trapping, a model has been presented [33] that relates fluoroquinolone accumulation in eukaryotic cells to their trapping under a protonated form in lysosomes due to the acid pH (~ 5.4) prevailing therein. This, however, is unlikely because fluoroquinolones are not weak bases but zwitterionic compounds. Moreover, differences in accumulation of drugs in acidic membrane-bounded compartments should result from

commensurate differences in the number and/or the pK_a of their basic functions (see [34]), which is not the case for the 3 fluoroquinolones studied here (see individual basic pK_a values in Table SP1). More factually, cell fractionation studies show a predominant association of the cell-associated fluoroquinolones with the cytosol rather than with lysosomes, in line with the results of previous studies with ciprofloxacin [2;35] (studies using the same technique have shown that macrolides are predominantly associated with lysosomes in J774 macrophages [2;36;37]). Lastly, experimental studies have shown a lack of effect of monensin (a H^+ ionophore that collapses the cytosolic-lysosomal ΔpH) on ciprofloxacin accumulation under conditions in which it drastically reduces the accumulation of azithromycin in J774 macrophages [9].

Actually, a more likely explanation for the larger cellular accumulation of gemifloxacin compared to moxifloxacin and ciprofloxacin could be its tighter binding to still undefined cellular constituents such as soluble proteins. This hypothesis would account for the pharmacokinetic and subcellular distribution data presented here, including (i) the lower efflux rate of gemifloxacin compared to ciprofloxacin (which, however, may also result from the less efficient recognition of gemifloxacin by the Mrp4 efflux transporter, both mechanisms being not mutually exclusive) and, (ii) its incomplete release upon transfer of the cells to drug-free medium. It is also consistent with the larger serum protein binding of gemifloxacin (55-73 %) compared to moxifloxacin (39-52 %) and ciprofloxacin (30 % only) [38;39].

Determining the molecular nature of the intracellular binding sites for fluoroquinolones still require further investigations, but the mechanism proposed provides a rational explanation for the main critical observation made here, namely that all 3 fluoroquinolones are equipotent against intracellular bacteria in spite of their differences in cellular accumulation. We show, indeed, that it is the MIC of each drug that drives its intracellular potency (as defined by the C_s and EC_{50} pharmacological descriptors) since all 3 fluoroquinolones show superimposable concentration-effects relationships once the data are normalized on basis of multiples of the

MIC. MICs are measured in broth where little protein binding takes place, which means that their values must essentially be interpreted as corresponding to free drug levels [40]. Intracellularly, a static effect (C_s) for gemifloxacin was obtained for an extracellular concentration corresponding to its MIC, although its intracellular concentration is much larger. It is, therefore, tempting to speculate that only a fraction of the total intracellular gemifloxacin is available for activity, corresponding essentially to its free form. Moxifloxacin should show an intermediate behaviour with intracellular activity also driven by its MIC (measured in broth), which is what we observe. Thus, the larger cellular accumulation of some fluoroquinolones, taking gemifloxacin an example, would essentially be a self-defeating process as far as activity is concerned (assuming all comparisons are made on basis of the MIC), leading to a larger concentration of bound drugs with, however, no or little difference in their free forms. This confirms and extends previous work that showed that the intracellular activity of fluoroquinolones was weaker and not in proportion to what could be anticipated from the level of their cellular accumulation [13;41-43].

In conclusion, the present work documents that (i) recording the cellular accumulation of fluoroquinolones does not allow to predict their intracellular activity; (ii) a higher cellular accumulation may depend from other parameters than influx and efflux rates and/or the activity of specific transporters. This calls for both more mechanistic studies and more comprehensive structure-activity analyses where these two important elements of the pharmacological properties of fluoroquinolones will be examined in a systematic fashion.

Acknowledgments

We are grateful to M.C. Cambier, C. Misson, and M. Vergauwen for dedicated technical assistance. We thank the Oscient Pharmaceuticals Corporation and Bayer HealthCare for the kind gift of gemifloxacin, and of moxifloxacin and ciprofloxacin, respectively.

Declarations

Funding: C.M.V. is Boursier of the Belgian *Fonds pour la Recherche dans l'Industrie et l'Agriculture* (F.R.I.A.), B.M. was post-doctoral fellow of the First post-doc programme of the Belgian *Région wallonne*, S.L. and F.V.B. are *Chargé de Recherches* and *Maître de Recherches* of the Belgian *Fonds de la Recherche Scientifique* (F.R.S.-FNRS), respectively. This work was supported by the Belgian *Fonds de la Recherche Scientifique Médicale* (grants no. 3.4.597.06 and 3.4.583.08) and the Belgian *Fonds de la Recherche Scientifique* (grant no. 1.5.195.07).

Competing interests: None

Ethical approval: Not applicable

References

- [1] Van Bambeke F, Michot JM, Van Eldere J, Tulkens PM. Quinolones in 2005: an update. *Clin Microbiol Infect* 2005; 11:256-280.
- [2] Seral C, Carryn S, Tulkens PM, Van Bambeke F. Influence of P-glycoprotein and MRP efflux pump inhibitors on the intracellular activity of azithromycin and ciprofloxacin in macrophages infected by *Listeria monocytogenes* or *Staphylococcus aureus*. *J Antimicrob Chemother* 2003; 51:1167-1173.
- [3] Lismond A, Tulkens PM, Mingeot-Leclercq MP, Courvalin P, Van Bambeke F. Cooperation between prokaryotic (Lde) and eukaryotic (MRP) efflux transporters in J774 macrophages infected with *Listeria monocytogenes*: studies with ciprofloxacin and moxifloxacin. *Antimicrob Agents Chemother* 2008; 52:3040-3046.
- [4] Hong CY, Kim YK, Chang JH, Kim SH, Choi H, Nam DH et al. Novel fluoroquinolone antibacterial agents containing oxime-substituted (aminomethyl)pyrrolidines: synthesis and antibacterial activity of 7-(4-(aminomethyl)-3-(methoxyimino)pyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro[1,8]naphthyridine-3-carboxylic acid (LB20304). *J Med Chem* 1997; 40:3584-3593.
- [5] Garcia I, Pascual A, Ballesta S, Joyanes P, Perea EJ. Intracellular penetration and activity of gemifloxacin in human polymorphonuclear leukocytes. *Antimicrob Agents Chemother* 2000; 44:3193-3195.
- [6] Baltch AL, Bopp LH, Smith RP, Michelsen PB, Ritz WJ. Antibacterial activities of gemifloxacin, levofloxacin, gatifloxacin, moxifloxacin and erythromycin against intracellular *Legionella pneumophila* and *Legionella micdadei* in human monocytes. *J Antimicrob Chemother* 2005; 56:104-109.

- [7] Renard C, Vanderhaeghe HJ, Claes PJ, Zenebergh A, Tulkens PM. Influence of conversion of penicillin G into a basic derivative on its accumulation and subcellular localization in cultured macrophages. *Antimicrob Agents Chemother* 1987; 31:410-416.
- [8] Marquez B, Caceres NE, Mingeot-Leclercq MP, Tulkens PM, Van Bambeke F. Identification of the efflux transporter of the fluoroquinolone antibiotic ciprofloxacin in murine macrophages: studies with ciprofloxacin-resistant cells. *Antimicrob Agents Chemother* 2009; 53:2410-2416.
- [9] Michot JM, Van Bambeke F, Mingeot-Leclercq MP, Tulkens PM. Active efflux of ciprofloxacin from J774 macrophages through an MRP-like transporter. *Antimicrob Agents Chemother* 2004; 48:2673-2682.
- [10] Michot JM, Seral C, Van Bambeke F, Mingeot-Leclercq MP, Tulkens PM. Influence of efflux transporters on the accumulation and efflux of four quinolones (ciprofloxacin, levofloxacin, garenoxacin, and moxifloxacin) in J774 macrophages. *Antimicrob Agents Chemother* 2005; 49:2429-2437.
- [11] Michot JM, Heremans MF, Caceres NE, Mingeot-Leclercq MP, Tulkens PM, Van Bambeke F. Cellular accumulation and activity of quinolones in ciprofloxacin-resistant J774 macrophages. *Antimicrob Agents Chemother* 2006; 50:1689-1695.
- [12] Tsuchiya S, Yamabe M, Yamaguchi Y, Kobayashi Y, Konno T, Tada K. Establishment and characterization of a human acute monocytic leukemia cell line (THP-1). *Int J Cancer* 1980; 26:171-176.
- [13] Carryn S, Van Bambeke F, Mingeot-Leclercq MP, Tulkens PM. Comparative intracellular (THP-1 macrophage) and extracellular activities of beta-lactams, azithromycin, gentamicin, and fluoroquinolones against *Listeria monocytogenes* at clinically relevant concentrations. *Antimicrob Agents Chemother* 2002; 46:2095-2103.

- [14] Barcia-Macay M, Seral C, Mingeot-Leclercq MP, Tulkens PM, Van Bambeke F. Pharmacodynamic evaluation of the intracellular activities of antibiotics against *Staphylococcus aureus* in a model of THP-1 macrophages. *Antimicrob Agents Chemother* 2006; 50:841-851.
- [15] Lowry OH, N.J.Rosebrough, A.L.Farr, R.J.Randall. Protein measurement with the Folin phenol reagent. *J Biol Chem* 1951; 193:265-275.
- [16] Anonymous. *Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically - Approved standard*. Clinical and Laboratory Standard Institute, Wayne, PA, 2010.
- [17] Lemaire S, Van Bambeke F, Mingeot-Leclercq MP, Tulkens PM. Activity of three β -lactams (ertapenem, meropenem and ampicillin) against intraphagocytic *Listeria monocytogenes* and *Staphylococcus aureus*. *J Antimicrob Chemother* 2005; 55:897-904.
- [18] Lemaire S, Van Bambeke F, Mingeot-Leclercq MP, Glupczynski Y, Tulkens PM. Role of acidic pH in the susceptibility of intraphagocytic methicillin-resistant *Staphylococcus aureus* strains to meropenem and cloxacillin. *Antimicrob Agents Chemother* 2007; 51:1627-1632.
- [19] Lemaire S, Kosowska-Shick K, Appelbaum PC, Glupczynski Y, Van Bambeke F, Tulkens PM. Activity of moxifloxacin against intracellular community-acquired methicillin-resistant *Staphylococcus aureus*: comparison with clindamycin, linezolid and co-trimoxazole and attempt at defining an intracellular susceptibility breakpoint. *J Antimicrob Chemother* 2011; 66:596-607.
- [20] Nguyen HA, Denis O, Vergison A, Theunis A, Tulkens PM, Struelens MJ et al. Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a *Staphylococcus aureus* small-colony variant strain isolated from a cystic fibrosis

- 410 patient: pharmacodynamic evaluation and comparison with isogenic normal-phenotype
411 and revertant strains. *Antimicrob Agents Chemother* 2009; 53:1434-1442.
- 412 [21] LG Life Sciences. LG Life Sciences 2009 Annual Report. 2010. Seoul, Korea, p. 18.
- 413 [22] Cormican MG, Jones RN. Antimicrobial activity and spectrum of LB20304, a novel
414 fluoronaphthyridone. *Antimicrob Agents Chemother* 1997; 41:204-211.
- 415 [23] Oh JI, Paek KS, Ahn MJ, Kim MY, Hong CY, Kim IC et al. In vitro and in vivo
416 evaluations of LB20304, a new fluoronaphthyridone. *Antimicrob Agents Chemother*
417 1996; 40:1564-1568.
- 418 [24] Roy B, Das A, Bhaumik U, Sarkar AK, Bose A, Mukharjee J et al. Determination of
419 gemifloxacin in different tissues of rat after oral dosing of gemifloxacin mesylate by LC-
420 MS/MS and its application in drug tissue distribution study. *J Pharm Biomed Anal* 2010;
421 52:216-226.
- 422 [25] Saravolatz LD, Leggett J. Gatifloxacin, gemifloxacin, and moxifloxacin: the role of 3
423 newer fluoroquinolones. *Clin Infect Dis* 2003; 37:1210-1215.
- 424 [26] Mandell LA, Iannini PB, Tillotson GS. Respiratory fluoroquinolones: differences in the
425 details. *Clin Infect Dis* 2004; 38:1331-1332.
- 426 [27] Capitano B, Mattoes HM, Shore E, O'Brien A, Braman S, Sutherland C et al. Steady-
427 state intrapulmonary concentrations of moxifloxacin, levofloxacin, and azithromycin in
428 older adults. *Chest* 2004; 125:965-973.
- 429 [28] Schuler P, Zemper K, Borner K, Koeppe P, Schaberg T, Lode H. Penetration of
430 sparfloxacin and ciprofloxacin into alveolar macrophages, epithelial lining fluid, and
431 polymorphonuclear leucocytes. *Eur Respir J* 1997; 10:1130-1136.

- 432 [29] Hara T, Takemura H, Kanemitsu K, Yamamoto H, Shimada J. Comparative uptake of
 433 grepafloxacin and ciprofloxacin by a human monocytic cell line, THP-1. *J Infect*
 434 *Chemother* 2000; 6:162-167.
- 435 [30] Bounds SJ, Nakkula R, Walters JD. Fluoroquinolone transport by human monocytes:
 436 characterization and comparison to other cells of myeloid lineage. *Antimicrob Agents*
 437 *Chemother* 2000; 44:2609-2614.
- 438 [31] Memin E, Panteix G, Revol A. Carrier-mediated system for pefloxacin uptake in human
 439 monocytes. *J Antimicrob Chemother* 1997; 40:263-268.
- 440 [32] Skazik C, Heise R, Bostanci O, Paul N, Denecke B, Joussen S et al. Differential
 441 expression of influx and efflux transport proteins in human antigen presenting cells. *Exp*
 442 *Dermatol* 2008; 17:739-747.
- 443 [33] Fresta M, Guccione S, Beccari AR, Furneri PM, Puglisi G. Combining molecular
 444 modeling with experimental methodologies: mechanism of membrane permeation and
 445 accumulation of ofloxacin. *Bioorg Med Chem* 2002; 10:3871-3889.
- 446 [34] de Duve C, de Barse T, Poole B, Trouet A, Tulkens P, Van Hoof F. Commentary.
 447 Lysosomotropic agents. *Biochem Pharmacol* 1974; 23:2495-2531.
- 448 [35] Carlier MB, Scorneaux B, Zenebergh A, Desnottes JF, Tulkens PM. Cellular uptake,
 449 localization and activity of fluoroquinolones in uninfected and infected macrophages. *J*
 450 *Antimicrob Chemother* 1990; 26 Suppl B:27-39.
- 451 [36] Carlier MB, Zenebergh A, Tulkens PM. Cellular uptake and subcellular distribution of
 452 roxithromycin and erythromycin in phagocytic cells. *J Antimicrob Chemother* 1987; 20
 453 Suppl B:47-56.

- [37] Carlier MB, Garcia-Luque I, Montenez JP, Tulkens PM, Piret J. Accumulation, release and subcellular localization of azithromycin in phagocytic and non-phagocytic cells in culture. *Int J Tissue React* 1994; 16:211-220.
- [38] Lode H, Hoffken G, Boeckk M, Deppermann N, Borner K, Koeppe P. Quinolone pharmacokinetics and metabolism. *J Antimicrob Chemother* 1990; 26 Suppl B:41-49.
- [39] Dudley MN. Pharmacokinetics of fluoroquinolones. In: Hooper DC, Wolfson JS, editors. *Quinolone Antimicrobial Agents*. Washington, DC: ASM Press, 2003: 115-132.
- [40] Schmidt S, Rock K, Sahre M, Burkhardt O, Brunner M, Lobmeyer MT et al. Effect of protein binding on the pharmacological activity of highly bound antibiotics. *Antimicrob Agents Chemother* 2008; 52:3994-4000.
- [41] Paillard D, Grellet J, Dubois V, Saux MC, Quentin C. Discrepancy between uptake and intracellular activity of moxifloxacin in a *Staphylococcus aureus*-human THP-1 monocytic cell model. *Antimicrob Agents Chemother* 2002; 46:288-293.
- [42] Seral C, Barcia-Macay M, Mingeot-Leclercq MP, Tulkens PM, Van Bambeke F. Comparative activity of quinolones (ciprofloxacin, levofloxacin, moxifloxacin and garenoxacin) against extracellular and intracellular infection by *Listeria monocytogenes* and *Staphylococcus aureus* in J774 macrophages. *J Antimicrob Chemother* 2005; 55:511-517.
- [43] Van de Velde S, Nguyen HA, Van Bambeke F, Tulkens PM, Grellet J, Dubois V et al. Contrasting effects of human THP-1 cell differentiation on levofloxacin and moxifloxacin intracellular accumulation and activity against *Staphylococcus aureus* and *Listeria monocytogenes*. *J Antimicrob Chemother* 2008; 62:518-521.

Table 1: Pertinent regression parameters ^a (with confidence intervals [CI]) and statistical analyses of data from experiments examining the concentration-response activities of ciprofloxacin, moxifloxacin and gemifloxacin (shown in Figure 3A). The 3 first rows show the analysis for each individual antibiotic and the last row the analysis made for all pooled data.

antibiotic	<i>L. monocytogenes</i>					<i>S. aureus</i>				
	R ²	E _{min} ^b (CI)	E _{max} ^c (CI)	EC ₅₀ ^d (CI)	C _s ^e	R ²	E _{min} ^b (CI)	E _{max} ^c (CI)	EC ₅₀ ^d (CI)	C _s ^e
ciprofloxacin	0.95	2.82 (1.83 to 3.81)	-3.96 (-5.44 to -2.48)	2.94 (1.00 to 8.66)	0.49	0.96	3.80 (2.92 to 4.68)	-1.60 (-2.26 to -0.94)	1.36 (0.64 to 2.89)	3.1
moxifloxacin	0.95	2.84 (2.05 to 3.63)	-4.48 (-5.21 to -3.56)	1.30 (0.62 to 2.74)	0.47	0.95	2.98 (2.11 to 3.86)	-1.85 (-2.28 to -1.43)	1.62 (0.78 to 3.38)	2.6
gemifloxacin	0.97	3.03 (1.79 to 4.27)	-3.55 (-4.28 to -2.82)	0.65 (0.27 to 1.59)	0.74	0.98	3.07 (2.32 to 3.83)	-1.30 (-1.64 to -0.97)	2.02 (1.01 to 4.03)	4.8
all 3	0.91	3.44 (2.95 to 3.94)	-3.92 (-4.53 to -3.32)	1.44 (0.95 to 2.19)	0.93	0.94	3.44 (2.95 to 3.94)	-1.55 (-1.81 to -1.29)	1.44 (0.95 to 2.19)	3.2

^a by use of all data for antibiotic concentrations ranging from approx. 0.01 to approx. 1,000 x MIC (ciprofloxacin: 0.01 to 100 mg/L [*L. monocytogenes*] and 0.001 to 100 mg/L [*S. aureus*]; moxifloxacin: 0.005 to 30 mg/L [*L. monocytogenes*] and 0.001 to 100 mg/L [*S. aureus*]; gemifloxacin: 0.005 to 150 mg/L [*L. monocytogenes*] and 0.0008 to 20 mg/L [*S. aureus*]).

^b relative minimal efficacy: change in cfu (in log₁₀ units) at time 24 h from the initial, post-phagocytosis inoculum, as extrapolated for an infinitely low antibiotic concentration

^c relative maximal efficacy: change in cfu (in log₁₀ units) at time 24 h from the initial, post-phagocytosis inoculum, as extrapolated for an infinitely large antibiotic concentration

489 ^d relative potency: extracellular concentration (in multiple of MIC) yielding a change in cfu at time 24 h half way between $E_{\min}$ and $E_{\max}$
490 ^e static concentration: concentration (in multiples of MIC) resulting no apparent bacterial growth (no change in cfu) from the initial, post-
491 phagocytosis inoculum), as determined by graphical intrapolation (MIC values (mg/L) are : 1 and 0.125 (ciprofloxacin), 0.5 and 0.03
492 (moxifloxacin), and 0.5 and 0.008 (gemifloxacin) for *L. monocytogenes* and *S. aureus* respectively.

493

494 Statistical analysis:

495 The raw data obtained for each individual antibiotic, and the corresponding Hill functions were compared using one way ANOVA (parametric)
496 and Kuskal-Wallis (non-parametric) tests found to be not significantly different (*L. monocytogenes*: $p = 0.420$ and 0.152 , respectively: *S.*
497 *aureus*: $p = 0.351$ and 0.249 , respectively). The analysis was then repeated for comparison of antibiotic pairs (ciprofloxacin vs. gemifloxacin;
498 ciprofloxacin vs. moxifloxacin; moxifloxacin vs. gemifloxacin) using unpaired t-test and showed no significant difference for any comparison
499 ($p > 0.18$).

500

Figure 1

Caption to Figure 1: Accumulation and efflux of fluoroquinolones.

A (upper panel): accumulation of gemifloxacin (GMF), moxifloxacin (MXF), and ciprofloxacin (CIP) in wild-type J774 mouse macrophages (left) and THP-1 human monocytes (right) incubated during 2 h with 20 mg/L in control conditions (open bars) or in the presence of the Mrp inhibitor gemfibrozil (500 µM; hatched bars). All values are the means of 3 independent determinations ± SD. Statistical analysis (ANOVA): control vs. gemfibrozil, *** $p < 0.001$; comparison of fluoroquinolones: bars with different letters are different from one another ($p < 0.001$; caps letters, control conditions; small letters, + gemfibrozil).

B (lower panel): kinetics of accumulation (left) and efflux (right) of gemifloxacin compared to ciprofloxacin in J774 macrophages (see [10] for efflux of moxifloxacin). For accumulation studies, cells were transferred to medium containing a fixed amount of drug (20 mg/L) and collected at the times indicated in the abscissa. For efflux, cells were first exposed to the drug for 2 h at a concentration of 20 mg/L, gently washed, transferred to drug free medium and collected at the times indicated in the abscissa. Data were used to fit a one phase exponential association function for influx $[y = y_{max} \times (1 - e^{-k_{in} \times t})]$ and a one phase exponential decay function for efflux $[y = y_{max} \times e^{-k_{out} \times t} + plateau]$ by nonlinear regression. Regression parameters for influx: (a) gemifloxacin, $R^2 = 0.780$, $k_{in} = 0.386 \pm 0.123 \text{ min}^{-1}$; (b) ciprofloxacin, $R^2 = 0.922$, $k_{in} = 0.348 \pm 0.066 \text{ min}^{-1}$. Regression parameters for efflux: (1) main graph, (a) gemifloxacin, $R^2 = 0.897$, $k_{out} = 0.403 \pm 0.122 \text{ min}^{-1}$, $plateau = 25.71 \pm 4.63$; (b) ciprofloxacin, $R^2 = 0.949$, $k_{out} = 0.949 \pm 0.204 \text{ min}^{-1}$, $plateau = 3.56 \pm 3.24$; (2) Inset: data for the initial stage of efflux (0 – 5 min) and corrected for differences in plateau reached after 10 min, (a) gemifloxacin, $R^2 = 0.658$, $k_{out} = 0.571 \pm 0.138 \text{ min}^{-1}$; (b) ciprofloxacin, $R^2 = 0.909$, $k_{out} = 1.216 \pm 0.209 \text{ min}^{-1}$. Statistical analysis (paired *t*- test two-tailed): Influx, no significant difference in rate constants; absolute values of plateaus of accumulation were different and in line with data of Figure 1). Efflux: Main graph, comparison of all values: $p < 0.001$, plateaus values only: $p < 0.001$, k values only: $p < 0.001$; Inset: comparison for all values: $p = 0.016$, k_{out} values only: $p < 0.001$.

536 **Figure 2**

537
 538 Caption to Figure 2: Cellular accumulation of gemifloxacin as compared to
 539 ciprofloxacin in wild-type or ciprofloxacin-resistant J774 mouse macrophages (see
 540 [11] for the corresponding data with moxifloxacin) **A** (upper panel): cells were
 541 incubated for 2 h in control conditions (open bars) or in ATP-depleted cells (gray
 542 hatched bars) with a fixed concentration (20 mg/L) of gemifloxacin (left) or
 543 ciprofloxacin (right) with wild-type cells (WT) or ciprofloxacin-resistant cells (CIP-R).
 544 Data are expressed in percentage of the value measured in wild-type cells in control
 545 conditions for each fluoroquinolone. All values are the means of 3 independent
 546 determinations $\pm$ SD. Statistical analysis (ANOVA): control vs. ATP-depletion, *** p
 547 < 0.001 ; WT vs. CIP-R cells: bars with different letters are different from one another
 548 ($p < 0.05$; upper case letters, control conditions; lower case letters, ATP-depletion).
 549 **B** (lower panel): Influence of the extracellular concentration of gemifloxacin (left) and
 550 ciprofloxacin (right) on their cellular to extracellular concentration ratio in wild-type

551 (closed symbols) or ciprofloxacin-resistant (open symbols) J774 mouse
552 macrophages, measured after 2 h of incubation. The cellular concentration was
553 expressed as μg per mg protein. Data are expressed in percentage of the highest
554 value observed in wild-type cells for each fluoroquinolone. All values are the means
555 of 3 independent determinations $\pm$ SD.

556

557

Figure 3

Caption to Figure 3: Concentration-response of the activities of gemifloxacin, moxifloxacin, and ciprofloxacin against phagocytized *L. monocytogenes* EGD (left) and *S. aureus* ATCC25923 (right) in wild-type J774 macrophages.

A (top): after phagocytosis and elimination of the extracellular bacteria, cells were incubated for 24 h with increasing concentrations of antibiotic (total drug) covering a ~ 0.01 to ~ 1,000 x MIC range (MIC [mg/L] were 1 and 0.125 [ciprofloxacin], 0.5 and 0.03 [moxifloxacin], and 0.5 and 0.008 [gemifloxacin] for *L. monocytogenes* and *S. aureus* respectively). The graphs show the change in the number of cfu (log scale) per mg of cell protein compared to the initial post-phagocytosis inoculum

(ordinate) as a function of the extracellular concentration of each drug expressed in multiple of its MIC (abscissa). In each graph, the horizontal dotted line corresponds to an apparent static effect and the vertical line to the MIC of the drug. A single sigmoidal regression has been fit to all data sets (see Figure SP2 for individual regression curves. The pertinent regression parameters and numerical values of the 4 key pharmacological descriptors ($E_{\min}$, $E_{\max}$, EC_{50} , C_s) are shown Table 1 for each drug - bacteria combination.

B (bottom): the ordinates show the calculated cellular concentrations (total drug; in multiples of MIC) needed to achieve two predefined activity levels (targets) shown on the abscissa (static effect [no apparent change in cfu]; 2 (*L. monocytogenes*) or 1 (*S. aureus*) $\log_{10}$ cfu decrease compared to the initial, post-phagocytosis inoculum). The cellular concentrations were calculated by (i) using the concentration-response curves shown in **A** to determine the extracellular concentrations needed to achieve the target effects (graphical intrapolation), and (ii) using the data of Figure 2B (wild type cells) to calculate the corresponding apparent total cellular concentrations of gemifloxacin and ciprofloxacin (for moxifloxacin, we used the accumulation data published in [10]) based on a conversion factor of 3.08 μ L of total cell volume per mg protein as determined experimentally for wild type J774 macrophages in previous studies [9].

Figure 4

Caption fo Figure 4: Subcellular distribution of gemifloxacin (GMF), moxifloxacin (MXF), and ciprofloxacin (CIP) in J774 mouse macrophages incubated for 2 h with 50 mg/L of each drug. The upper panel shows the antibiotic content in the nuclear/unbroken cells, organelles, and soluble fractions expressed in percentage of the total recovered amount (each bar corresponds to a separate experiment). The lower panel shows the distribution of lactate dehydrogenase (LDH; marker of the cytosol), cytochrome-c-oxydase (CYTOX; marker of mitochondria), and N-acetyl- β -hexosaminidase (NAB; marker of lysosomes) as the mean values ($\pm$ SD) of the 3 experiments (corresponding to each of the individual experiment shown in the upper panel).

Vallet *et al.* Intracellular activity of fluoroquinolones - Supplementary Material

Figure SP1

Caption to Figure SP1: Kinetics of efflux of gemifloxacin from wild-type and ciprofloxacin-resistant J774 cells. Cells were exposed to gemifloxacin (20 mg/L) for 2 h and then transferred to antibiotic-free medium for up to 30 min. Regression parameters: (a) wild-type cells (same data as in Figure 2), $R^2 = 0.896$, $k_{out} = 0.403 \pm 0.122 \text{ min}^{-1}$, $plateau = 25.71 \pm 4.63$; (b) ciprofloxacin-resistant cells, $R^2 = 0.830$, $k_{out} = 2.39 \pm 0.907 \text{ min}^{-1}$, $plateau = 31.6 \pm 4.0$.

Figure SP2

Caption to Figure SP2: Concentration-response of the activities of gemifloxacin, moxifloxacin, and ciprofloxacin (CIP) against *S. aureus* ATCC25923 (top) and *L. monocytogenes* EGD (bottom) in wild-type J774 macrophages. Cells were incubated with increasing concentrations of antibiotic (total drug) for 24 h. Each graph shows the change in the number of cfu (log scale) per mg of cell protein compared to the initial post-phagocytosis inoculum (ordinate) as a function of the extracellular concentration of each drug expressed in multiples of its MIC (abscissa). In each graph, the horizontal dotted line corresponds to an apparent static effect and the vertical line to the MIC of the drug. A sigmoidal regression has been fitted to each set of data (see Table 1 for the pertinent regression parameters and numerical values of the four key pharmacological descriptors ($E_{\min}$, $E_{\max}$, EC_{50} , C_s)).

Table SP1: Physico-chemical properties of fluoroquinolones and azithromycin at physiologically-relevant pHs

The data indicate that (i) ciprofloxacin, moxifloxacin, and gemifloxacin display quite similar biophysical properties although showing distinct cellular accumulation levels (gemifloxacin > moxifloxacin > ciprofloxacin; see Results) that are not correlated to the minor differences seen; (ii) these properties are very different from those of azithromycin, a drug known to accumulate extensively in lysosomes by proton-trapping (see Discussion). The pHs considered are those of the extracellular (7-7.4) and of the lysosomal (5-5.4) milieus, respectively.

637

Drug	pKa ₁ ^a (acidic)	pKa ₂ ^a (basic)	species in solution (calculated %) ^a						logP ^b		calculated logD ^{a,c}	
			pH 7.4			pH 5.4			calculated ^{a,d}	experimental ^e	pH 7	pH 5
			cationic	zwitterionic	anionic	cationic	zwitterionic	anionic				
ciprofloxacin	5.8	8.7	2	93	5	69	30	0	1.63 ^c	2.30	-1.38	-1.62
moxifloxacin	5.6	9.4	2	97	1	66	34	0	1.90	2.90	-1.72	-1.33
gemifloxacin	5.5	9.5	1	98	1	47	52	0	1.04	2.30	-2.54	-1.78
azithromycin	-	8.9 ^f 9.6	96.98 ^g	0.02	0	99.97 ^g	0	0	2.44	4.02	-1.99	-4.41

638

^a calculated using Reaxys (<http://www.reaxys.com>) with the ChemAxon's Marvin plug-in calculators (<http://www.chemaxon.com/marvin>). The actual values of the pK_a of the acidic function may be about 0.5 units higher due to the influence of the vicinal carbonyl function [1].

^b logP: partition coefficient (log of the ratio of the concentrations of the unionized compound between a non polar [octanol] and a polar [water] phases);

643 ^c logD: distribution coefficient (log of the ratio of the sum of the concentrations of all forms of the compound [ionized plus un-ionized] in each of
644 the two phases at a given pH)

645 ^d These values are the arithmetic average of three methods of calculations (Viswanadhan's fragmentation; Klopman's fragmentation; and
646 PHYSPROP© database [see https://www.reaxys.com/static/marvin/marvin_5_3_7/help/calculations/partitioning.html for details]).

647 ^e value as reported in Drugbank (see <http://www.drugbank.ca> and [2])

648 ^f azithromycin is a dicationic drug

649 ^g dicationic form (monocationic form: 3 % at pH 7.4 and 0.03 % at pH 5.4; a zwitterionic form is virtually inexistent (< 0.001 %) at these pH
650 values).

651
652 References

653
654 [1] Nikaido H, Thanassi DG. Penetration of lipophilic agents with multiple protonation sites into bacterial cells: tetracyclines and
655 fluoroquinolones as examples. *Antimicrob Agents Chemother.* 1993 Jul;37(7):1393-9. [PMID: 8363364]

656
657 [2] Wishart DS, Knox C, Guo AC, Shrivastava S, Hassanali M, Stothard P, Chang Z, Woolsey J: DrugBank, a comprehensive resource for *in*
658 *silico* drug discovery and exploration, *Nucleic Acids Res.* 2006 Jan 1;34 (Database issue): D668-72 [PMID: 16381955]

659
660